A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US
Known as a fervent watchdog over the prices and cost-effectiveness of new pharmaceuticals, the Institute for Clinical and Economic Review (ICER) said in a report published early Thursday that all four Covid-19 outpatient treatments’ prices are adequately aligned with their benefits.
The review covered the only mAb treatment that works against Omicron — GSK and Vir’s sotrovimab — Pfizer’s highly effective pill Paxlovid, Merck’s less effective pill molnupiravir and the cheaper generic drug fluvoxamine, that has yet to receive an EUA from FDA as a Covid-19 treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
